Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Army
Fish and Richardson
Colorcon
Queensland Health
Cantor Fitzgerald
McKinsey
US Department of Justice
UBS

Generated: April 24, 2018

DrugPatentWatch Database Preview

MAXALT Drug Profile

« Back to Dashboard

Which patents cover Maxalt, and what generic alternatives are available?

Maxalt is a drug marketed by Merck and is included in two NDAs.

The generic ingredient in MAXALT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
Summary for MAXALT
Drug patent expirations by year for MAXALT
Synonyms for MAXALT
145202-66-0
1H-Indole-3-ehtanamine,N,N-dimehtyl-5-(1H-1,2,4-triazol-1-ylmethyl)-,monobenzoate
1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, monobenzoate
2-(5-((1H-1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)-N,N-dimethylethan-1-amine benzoate
2-(5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-1H-INDOL-3-YL)-N,N-DIMETHYLETHANAMINE BENZOATE
202R660
3-(2-(Dimethylamino)ethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)indole monobenzoate
AB0011227
AB07521
AB2000157
ABP000203
AC-734
AC1L2U9K
ACT04340
AK163196
AKOS015855933
AN-15582
API0004087
AX8006648
BC208268
benzoic acid; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
benzoic acid; rizatriptan
benzoic acid;N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
BG0594
C15H19N5.C7H6O2
CCG-101039
CHEBI:8875
CHEMBL1201032
CPD000525252
CS-2147
D00675
DIMETHYL-[2-(5-[1,2,4]TRIAZOL-1-YLMETHYL-1H-INDOL-3-YL)-ETHYL]-AMINE BENZOATE
DTXSID20162937
FT-0631171
HE311948
HMS2051B16
HMS2093K08
HMS2235M18
HMS3369I15
HMS3393B16
HMS3655K09
HY-B0206
I01-0305
IN2169
INT-0008
J-008071
J-524222
JPRXYLQNJJVCMZ-UHFFFAOYSA-N
KS-00000XKR
KS-1189
L 705,126
L 705126
L-705,126
L-705126
LS-173238
MFCD00866224
MK 0462
MK 462
MK-0462
MK-462
MK-462 BENZOATE SALT
MK-462;Maxalt;Maxalt
MLS001424197
MolPort-003-850-198
N,N-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1H-indole-3-yl)ethylamine
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine benzoate
N,N-DIMETHYL-2-[5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHYLAMINE BENZOATE SALT
N,N-DIMETHYL-2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHANAMINE BENZOATE
N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOLE-3-ETHANAMINE BENZOATE
NC00289
NSC-758919
NSC758919
Pharmakon1600-01505189
R0107
R0181
RHB-103
rizatrimptan benzoate
Rizatriptan (benzoate)
Rizatriptan benzoate
Rizatriptan benzoate (JAN/USAN)
Rizatriptan Benzoate (Maxalt)
Rizatriptan benzoate [USAN:USP]
Rizatriptan Benzoate [USAN]
RIZATRIPTAN BENZOATE SALT
Rizatriptan benzoate salt, >=98% (HPLC)
Rizatriptan benzoate, European Pharmacopoeia (EP) Reference Standard
Rizatriptan benzoate, United States Pharmacopeia (USP) Reference Standard
Rizatriptan Benzoate(Maxalt)/
Rizatriptan for system suitability, European Pharmacopoeia (EP) Reference Standard
RIZATRIPTAN MONOBENZOATE
rizatriptan, benzoate
Rizatriptan(RIZ)
Rizatriptanbenzoate
rizatriptane benzoate
RL01822
S1607
SAM001246615
SCHEMBL41226
SMR000525252
ST24039483
ST51051528
UNII-WR978S7QHH
WR978S7QHH
X-2040

US Patents and Regulatory Information for MAXALT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-001 Jun 29, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-002 Jun 29, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for MAXALT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-002 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-002 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-001 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-001 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MAXALT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2006-02-17
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2004-09-02

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Dow
Chubb
Cantor Fitzgerald
Deloitte
Chinese Patent Office
Colorcon
Medtronic
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.